Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

C Hage; V Rausch; N Giese; T Giese; F Schönsiegel; S Labsch; C Nwaeburu; J Mattern; J Gladkich; I Herr

doi:10.1038/s41419-023-06385-9

Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

Cell Death Dis. 2024 Jan 29;15(1):96. doi: 10.1038/s41419-023-06385-9.

Authors

C Hage^{1

2}, V Rausch^{1

2}, N Giese², T Giese³, F Schönsiegel^{1

2}, S Labsch^{1

2}, C Nwaeburu^{1

2}, J Mattern^{1

2}, J Gladkich^{1

2}, I Herr^{4

5}

Affiliations

¹ Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg, Heidelberg, Germany.
² Department of General Surgery, Institute for Immunology, University of Heidelberg, Heidelberg, Germany.
³ Department of Molecular Immunodiagnostics, Institute for Immunology, University of Heidelberg, Heidelberg, Germany.
⁴ Section Surgical Research, Molecular OncoSurgery, University Clinic of Heidelberg, Heidelberg, Germany. i.herr@uni-heidelberg.de.
⁵ Department of General Surgery, Institute for Immunology, University of Heidelberg, Heidelberg, Germany. i.herr@uni-heidelberg.de.

No abstract available

Publication types

Published Erratum